This course is available for purchase as part of a subscription:
Time to Complete
October 6, 2016
November 14, 2017
Dr Tabi Leslie reviews the current guidelines for chronic spontaneous urticaria, including the EAACI, BAD, BSACI and AAAAI guidelines, and recent NICE guidance on use of omalizumab in previously treated chronic spontaneous urticaria.
After taking this activity, healthcare professionals should be better able to:
Understand the current guidelines on chronic spontaneous urticaria
Understand the use of omalizumab in CSU
Activity author Dr Tabi Leslie Consultant dermatologist Royal Free Hospital London UK
This is a learning activity provided by MIMS Learning, featuring learning material and a test. Completing the test enables you to claim 0.5 learning credits (0.5 hours learning). This credit award is recommended by MIMS Learning based on completing the activity and reflecting on what you have learned. If you spend less time on the activity we recommend claiming fewer credits.
Please proceed with the activity until you have successfully answered all the test questions and completed your evaluation. You will then receive your MIMS Learning CPD certificate, which will be added to your CPD organiser for access at any time and may be exported to the Clarity & RCGP Appraisal Toolkit for GPs.
Hardware and Software Requirements
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required